Bioventus (BVS) Short-term Investments (2021 - 2022)
Bioventus (BVS) posted Short-term Investments of $23000.0 for Q4 2022, little changed on a QoQ basis from $23000.0 in Q4 2022, and down 99.56% year-over-year from $5.3 million in Q4 2021.
Bioventus (BVS) Short-term Investments (2021 - 2022) Analysis & Trends
Bioventus' Short-term Investments history runs 2 years deep, the most recent figure standing at $23000.0 for Q4 2022.
- Quarterly Short-term Investments fell 99.56% year-over-year to $23000.0 in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $23000.0 (down 99.56% YoY) and the FY2022 annual result came in at $23000.0, down 99.56% from the prior year.
- Short-term Investments was $23000.0 for Q4 2022 at Bioventus, roughly flat from $23000.0 in the prior quarter.
- Across five years, Short-term Investments topped out at $5.3 million in Q4 2021 and bottomed at $23000.0 in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 182.30 Bn | 175.00 Bn | 6.27 Bn |
| 2 | Stryker | 128.77 Bn | 125.89 Bn | 3.81 Bn |
| 3 | Medtronic | 107.99 Bn | 98.77 Bn | 6.41 Bn |
| 4 | Boston Scientific | 67.85 Bn | 66.39 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 48.12 Bn | 44.45 Bn | 1.29 Bn |
| 6 | Dexcom | 28.26 Bn | 27.14 Bn | 750.30 Mn |
| 7 | GE HealthCare Technologies | 27.98 Bn | 25.70 Bn | 1.98 Bn |
| 8 | Smith & Nephew | 26.99 Bn | 26.41 Bn | - |
| 9 | Koninklijke Philips | 23.78 Bn | 20.65 Bn | 2.07 Bn |
| 10 | Bioventus | 831.78 Mn | 795.94 Mn | 90.77 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 23,000.00 |
| Oct 1, 2022 | 23,000.00 |
| Apr 2, 2022 | 5.28 Mn |
| Dec 31, 2021 | 5.28 Mn |
| Jul 3, 2021 | 2.00 Mn |
| Apr 3, 2021 | 5.21 Mn |